DaVita Shares Plunge 9% Amid 150% Volume Surge to $430M, Rank 264th in Market Activity

On August 6, 2025, DaVita (DVA) shares fell 9.04% with a trading volume of $0.43 billion, marking a 150.73% surge in activity compared to the previous day. The stock ranked 264th in trading volume across the market.

The decline followed DaVita’s second-quarter earnings report, which revealed a 1.1% year-over-year drop in U.S. patient treatment volumes, below internal projections. The company revised its full-year treatment volume forecast downward, citing operational challenges. A $13 million cybersecurity incident further pressured revenue per treatment, compounding investor concerns. Deutsche Bank responded by cutting its price target to $137 from $165, amplifying the sell-off.

Despite beating adjusted EPS estimates by 9.3% and reporting a 6.1% revenue increase to $3.38 billion, DaVita’s shares underperformed. Gross margin expanded 31 basis points to 33.1%, and dialysis patient service revenue grew 4.8% year-over-year. However, normalized non-acquired treatment volumes fell 0.8% annually, signaling ongoing growth headwinds. The firm maintained its adjusted EPS guidance of $10.20–$11.30 for 2025 but acknowledged center closures and declining patient counts as persistent risks.

A strategy of purchasing the top 500 stocks by daily trading volume and holding for one day generated a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This highlights liquidity concentration’s role in short-term performance, particularly in volatile markets. The approach underscores how high-volume stocks can drive returns but also emphasizes the risks of rapid market shifts and liquidity-driven volatility.